Video

Achieving Value in Specialty Pharmacy

Author(s):

Davy James, Managing Editor

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the cost burden of long term care compared with the high cost of short term treatment with specialty drugs.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the cost burden of long term care compared with the high cost of short term treatment with specialty drugs.

Related Videos
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com
Related Content
Drug Prices, Ozempic, Biktarvy | Image Credit: lucid_dream | stock.adobe.com
January 21st 2025

Ozempic, Biktarvy Among the Drugs Seeing List Price Increases at the Start of 2025

Ashley Gallagher, Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

GLP-1, Diabetes, Type 2 Diabetes | Image Credit: © neirfy | stock.adobe.com
January 20th 2025

ASHP Midyear: Expert Discusses GLP-1 Medications and Incretin Mimetics for Diabetes Care

Ashley Gallagher, Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Psilocybin therapy -- Image credit: TaylerDerden | stock.adobe.com
January 17th 2025

Psilocybin May Improve Mental Health Symptoms in Patients With Cancer and Addiction

Gillian McGovern, Associate Editor
Blood sample testing for hepatitis B virus -- Image credit: gamjai | stock.adobe.com
January 17th 2025

Xalnesiran Plus Immunomodulator Results in HBsAg Loss Among Patients With Chronic Hepatitis B

Gillian McGovern, Associate Editor